Key result
SAMe-TT₂R₂ score fails to predict suboptimal TTR in Thai patients with AF.
Why the study?
Does the SAMe-TT₂R₂ score predict suboptimal time in therapeutic range (TTR) in Thai patients with non-valvular atrial fibrillation on warfarin?
Cohort (n=140)
No
Does the SAMe-TT₂R₂ score predict suboptimal time in therapeutic range (TTR) in Thai patients with non-valvular atrial fibrillation on warfarin?
The SAMe-TT₂R₂ score has poor predictive performance for suboptimal TTR in Thai patients with non-valvular AF, suggesting clinical decisions should rely on actual TTR rather than the score.
Answers are grounded in this paper and cite their sources.
Does not support SAMe-TT₂R₂ use for TTR prediction in Thai AF; leaves open validation of population-specific tools.
BACKGROUND: The SAMe-TT₂R₂ score is used to predict poor anticoagulation control (time in therapeutic range (TTR)) in warfarin users. However, its performance varies across ethnicities, and its validity in the Thai population is uncertain. This study aimed to evaluate the score's predictive performance and redefine the optimal cutoff for Thai patients with atrial fibrillation (AF). METHODOLOGY: This retrospective analysis included 140 patients with non-valvular AF on warfarin at a single University Hospital. TTR was calculated using the Rosendaal method, with suboptimal control defined as TTR <70%. The score's overall predictive performance was assessed using the area under the ROC curve (AUC). RESULTS: The mean of TTR was 59.89% ± 28.56%, and 83 patients (59.3%) had suboptimal TTR. The SAMe-TT₂R₂ score ≥3 demonstrated poor predictive ability for suboptimal TTR (AUC = 0.55; 95% confidence interval (CI), 0.50-0.60). At this cutoff, key diagnostic metrics included high sensitivity (95.2%) but extremely low specificity (14.0%), a modest positive predictive value (PPV) of 61.7% and a low negative predictive value (NPV) of 66.7%. Notably, in multivariable analysis, age <60 years, a risk factor in the original score, was independently associated with a lower risk of suboptimal TTR. A longer duration of warfarin use was also associated with a lower risk of suboptimal TTR. CONCLUSIONS: patients at risk for poor control. Clinical decisions, such as intensive monitoring or switching to a direct oral anticoagulant (DOAC), should be guided by a patient's actual TTR rather than the SAMe-TT₂R₂ score. The single-center, retrospective design and modest sample size limit generalizability and statistical power, necessitating a further prospective trial for validation.
No takes yet. Share an insight, caveat, or question.
Manasirisuk et al. (2025) conducted a cohort in Non-valvular atrial fibrillation (n=140). SAMe-TT₂R₂ score ≥3 vs. SAMe-TT₂R₂ score <3 was evaluated on Predictive performance for suboptimal time in therapeutic range (TTR <70%) (AUC 0.55, 95% CI 0.50-0.60). The SAMe-TT₂R₂ score ≥3 demonstrated poor predictive ability for suboptimal time in therapeutic range in Thai patients with atrial fibrillation, yielding an AUC of 0.55.
Synapse has enriched 10 related papers. Consider them for comparative context: